1005768-69-3

Upstream product

• 634181-78-5 (R)-4-((R)-1-(benzyloxy)-2,2-difluorobut-3-en-1-yl)-2,2-dimethyl-1,3-dioxolane 

Downstream Products

• 1005768-70-6 (2R,3R)-1-O-benzoyl-3-O-benzyl-4,4-difluoro-5-hexene-1,2,3-triol 
• 1369405-98-0 (2S,4R,5S,6R)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-3,3-difluoro-6-(4-methyl-3-(4-propoxybenzyl)phenyl)tetrahydro-2H-pyran 
• 1369405-68-4 (2R,3R,4R,6S)-5,5-difluoro-6-(hydroxymethyl)-2-(3-(4-methoxybenzyl)-4-methylphenyl)tetrahydro-2H-pyran-3,4-diol 
• 1369405-69-5 (2R,3R,4R,6S)-2-(3-(4-ethylbenzyl)-4-methylphenyl)-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol 
• 1369405-87-7 (2R,3S,4R,6S)-2-(4-chloro-3-(4-methylbenzyl)phenyl)-5,5-difluoro-6-(((4-nitrobenzoyl)oxy)methyl)tetrahydro-2H-pyran-3,4-diyl bis(4-nitrobenzoate) 
• 1369405-71-9 (S)-2-((R)-1-(benzyloxy)-2,2-difluorobut-3-en-1-yl)oxirane 
• 1369405-72-0 (2S,3R)-3-(benzyloxy)-4,4-difluorohex-5-ene-1,2-diyl diacetate 
• 1369405-73-1 C₁₃H₁₆F₂O₃ 
• 1369405-74-2 (2S,3R)-3-(benzyloxy)-1-((tert-butyldimethylsilyl)oxy)-4,4-difluorohex-5-en-2-ol 
• 1369405-75-3 (((2S,3R)-2,3-bis(benzyloxy)-4,4-difluorohex-5-en-1-yl)oxy)(tert-butyl)dimethylsilane 
• 1369405-76-4 C₂₆H₃₈F₂O₅Si 
• 1369405-77-5 (2R,4R,5S)-1,4,5-tris(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)-3,3-difluorohexan-2-ol 
• 1369405-78-6 (2S,4R,5S)-1,4,5-tris(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)-3,3-difluorohexan-2-ol 
• 1369405-79-7 (2S,3R,5R)-2,3,6-tris(benzyloxy)-4,4-difluorohexane-1,5-diol 

Relevant academic research and scientific papers

Synthesis and biological evaluation of SGLT2 inhibitors: Gem-difluoromethylenated Dapagliflozin analogs

Dapagliflozin is currently the most advanced SGLT2 inhibitor, which has been used in Phase III clinical trials for treatment of diabetes. Here we describe the design and synthesis of Dapagliflozin analogs modified with gem-difluoromethylene group. Their b

Synthesis of gem-difluorinated nucleoside analogues of the liposidomycins and evaluation as MraY inhibitors

Two gem-difluoromethylenated nucleoside moieties of liposidomycins, 3 and 4, were designed and synthesized. Compound 3 was assembled from lactol 5 and gem-difluoromethylenated nucleoside 6. In the synthesis of target molecule 4, the coupling of the trichl